<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 週一下跌了 8.2%。該公司交易最低價為 $42.19，最後交易價為 $41.39。在交易過程中，約有 9,467,116 股易手，較日均交易量 22,015,939 股下降了 57%。該股票此前收盤價為 $45.09。</p>
<p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>錯過了 Hims &amp; Hers 的反彈？Clover Health 可能是下一個</li>
</ul>
<p>幾家研究公司已對 HIMS 發佈了報告。Truist Financial 將 Hims &amp; Hers Health 的目標價從 $24.00 上調至 $39.00，並在 2 月 26 日的研究報告中給予該公司 &#34;持有&#34; 評級。德意志銀行將 Hims &amp; Hers Health 的目標價從 $23.00 上調至 $27.00，並在 11 月 6 日的研究報告中給予該股票 &#34;持有&#34; 評級。花旗集團將 Hims &amp; Hers Health 的目標價從 $25.00 上調至 $27.00，並在 2 月 25 日的研究報告中給予該公司 &#34;賣出&#34; 評級。Leerink Partners 將 Hims &amp; Hers Health 的目標價從 $24.00 上調至 $40.00，並在 2 月 25 日的報告中給予該股票 &#34;市場表現&#34; 評級。最後，美國銀行將 Hims &amp; Hers Health 的目標價從 $18.00 上調至 $21.00，並在 2 月 20 日的報告中給予該公司 &#34;表現不佳&#34; 評級。兩位投資分析師給予該股票 &#34;賣出&#34; 評級，七位給予 &#34;持有&#34; 評級，六位給予該公司 &#34;買入&#34; 評級。根據 MarketBeat 的數據，Hims &amp; Hers Health 目前的平均評級為 &#34;持有&#34;，共識目標價為 $37.23。</p>
<p><strong>閲讀我們關於 Hims &amp; Hers Health 的最新報告</strong></p>
<h2>Hims &amp; Hers Health 股票表現</h2>
<ul>
<li>華爾街最受歡迎：當前 2 只高度被做空的股票</li>
</ul>
<p>該公司的 50 日簡單移動平均線為 $36.57，200 日簡單移動平均線為 $26.82。該公司的市值為 $90.3 億，市盈率為 92.39，貝塔值為 1.35。</p>
<p>Hims &amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近一次發佈財報是在 2 月 24 日，報告每股收益 (EPS) 為 $0.11，超出分析師共識預期的 $0.09，超出幅度為 $0.02。該公司在該季度的收入為 $4.8114 億，而共識預期為 $4.9456 億。Hims &amp; Hers Health 的淨利潤率為 8.19%，股本回報率為 10.97%。作為一個整體，賣方分析師預測 Hims &amp; Hers Health, Inc. 本年度將發佈每股收益 0.29。</p>
<h2>內部買賣</h2>
<ul>
<li>MarketBeat 週迴顧 – 02/17 - 02/21</li>
</ul>
<p>在其他新聞中，首席財務官 Oluyemi Okupe 於 1 月 13 日星期一出售了 11,581 股該股票，交易均價為 $24.44，總交易額為 $283,039.64。出售後，首席財務官現在直接持有該公司 118,077 股股票，價值 $2,885,801.88。這代表其持股減少了 8.93%。該交易已在與 SEC 的法律文件中披露，鏈接可通過此處獲取。此外，內部人士 Michael Chi 於 2 月 24 日星期一出售了 17,303 股該股票，交易均價為 $48.14，總價值為 $832,966.42。交易後，內部人士現在持有該公司 193,601 股股票，價值約 $9,319,952.14。這代表其持股減少了 8.20%。該交易的披露信息可在此處找到。內部人士在過去九十天內共出售了 1,062,011 股公司股票，價值 $36,892,724。公司內部人士持有公司股票的 17.71%。</p>
<h2>機構資金流入和流出</h2>
<p>幾家對沖基金最近買賣了該股票的股份。Crewe Advisors LLC 在第四季度購買了 Hims &amp; Hers Health 的新頭寸，價值約 $28,000。Raleigh Capital Management Inc. 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 $29,000，此前在上個季度購買了額外的 1,100 股。Blume Capital Management Inc. 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 $29,000，此前在該期間購買了額外的 600 股。Smartleaf Asset Management LLC 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 現在擁有該公司 1,445 股股票，價值 $36,000，此前在上個季度購買了額外的 1,413 股。最後，Summit Securities Group LLC 在第四季度購買了 Hims &amp; Hers Health 的新股份，價值 $38,000。對沖基金和其他機構投資者持有公司 63.52% 的股票。</p>
<h2>關於 Hims &amp; Hers Health</h2>
<p>(獲取免費報告)</p>
<p>Hims &amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Hims &amp; Hers Health</li>
<li>每月分紅股票的利弊</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求避難所</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>3 只超賣的傑出七隻股票處於關鍵水平：現在買入？</li>
<li>投資者如何識別併成功交易下跌股票</li>
<li>3M 到中期將達到 $175，且更高的高點很可能出現</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在你考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

<p>Hims & Hers Health（紐約證券交易所代碼：HIMS）股票下跌 8.2%，至 41.39 美元，交易量較平均水平下降 57%。分析師的評級意見不一，其中兩家為賣出，七家為持有，六家為買入。平均目標價為 37.23 美元。公司報告每股收益為 0.11 美元，超出預期，但營收為 4.8114 億美元，未達到預期。內部人士的賣出行為引起關注，近期有大量股份被出售。對沖基金也表現活躍，上個季度報告了新頭寸和增持股份</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) was down 8.2% on Monday . The company traded as low as $42.19 and last traded at $41.39. Approximately 9,467,116 shares changed hands during trading, a decline of 57% from the average daily volume of 22,015,939 shares. The stock had previously closed at $45.09.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 週一下跌了 8.2%。該公司交易最低價為 $42.19，最後交易價為 $41.39。在交易過程中，約有 9,467,116 股易手，較日均交易量 22,015,939 股下降了 57%。該股票此前收盤價為 $45.09。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Missed the Hims &amp; Hers Rally? Clover Health Could Be Next</li>
</ul>
<div class="lb-trans"><ul>
<li>錯過了 Hims &amp; Hers 的反彈？Clover Health 可能是下一個</li>
</ul>
</div><p>Several research firms have issued reports on HIMS. Truist Financial lifted their target price on Hims &amp; Hers Health from $24.00 to $39.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, February 26th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims &amp; Hers Health from $23.00 to $27.00 and gave the stock a &#34;hold&#34; rating in a research report on Wednesday, November 6th. Citigroup increased their target price on shares of Hims &amp; Hers Health from $25.00 to $27.00 and gave the company a &#34;sell&#34; rating in a research report on Tuesday, February 25th. Leerink Partners lifted their price target on shares of Hims &amp; Hers Health from $24.00 to $40.00 and gave the stock a &#34;market perform&#34; rating in a report on Tuesday, February 25th. Finally, Bank of America increased their price objective on Hims &amp; Hers Health from $18.00 to $21.00 and gave the company an &#34;underperform&#34; rating in a report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Hims &amp; Hers Health presently has an average rating of &#34;Hold&#34; and a consensus price target of $37.23.</p>
<div class="lb-trans"><p>幾家研究公司已對 HIMS 發佈了報告。Truist Financial 將 Hims &amp; Hers Health 的目標價從 $24.00 上調至 $39.00，並在 2 月 26 日的研究報告中給予該公司 &#34;持有&#34; 評級。德意志銀行將 Hims &amp; Hers Health 的目標價從 $23.00 上調至 $27.00，並在 11 月 6 日的研究報告中給予該股票 &#34;持有&#34; 評級。花旗集團將 Hims &amp; Hers Health 的目標價從 $25.00 上調至 $27.00，並在 2 月 25 日的研究報告中給予該公司 &#34;賣出&#34; 評級。Leerink Partners 將 Hims &amp; Hers Health 的目標價從 $24.00 上調至 $40.00，並在 2 月 25 日的報告中給予該股票 &#34;市場表現&#34; 評級。最後，美國銀行將 Hims &amp; Hers Health 的目標價從 $18.00 上調至 $21.00，並在 2 月 20 日的報告中給予該公司 &#34;表現不佳&#34; 評級。兩位投資分析師給予該股票 &#34;賣出&#34; 評級，七位給予 &#34;持有&#34; 評級，六位給予該公司 &#34;買入&#34; 評級。根據 MarketBeat 的數據，Hims &amp; Hers Health 目前的平均評級為 &#34;持有&#34;，共識目標價為 $37.23。</p>
</div><p><strong>Read Our Latest Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Hims &amp; Hers Health 的最新報告</strong></p>
</div><h2>Hims &amp; Hers Health Stock Performance</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 股票表現</h2>
</div><ul>
<li>Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>華爾街最受歡迎：當前 2 只高度被做空的股票</li>
</ul>
</div><p>The firm's 50 day simple moving average is $36.57 and its 200 day simple moving average is $26.82. The firm has a market capitalization of $9.03 billion, a price-to-earnings ratio of 92.39 and a beta of 1.35.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 $36.57，200 日簡單移動平均線為 $26.82。該公司的市值為 $90.3 億，市盈率為 92.39，貝塔值為 1.35。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts forecast that Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近一次發佈財報是在 2 月 24 日，報告每股收益 (EPS) 為 $0.11，超出分析師共識預期的 $0.09，超出幅度為 $0.02。該公司在該季度的收入為 $4.8114 億，而共識預期為 $4.9456 億。Hims &amp; Hers Health 的淨利潤率為 8.19%，股本回報率為 10.97%。作為一個整體，賣方分析師預測 Hims &amp; Hers Health, Inc. 本年度將發佈每股收益 0.29。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><ul>
<li>MarketBeat Week in Review – 02/17 - 02/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/17 - 02/21</li>
</ul>
</div><p>In other news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $24.44, for a total transaction of $283,039.64. Following the sale, the chief financial officer now directly owns 118,077 shares of the company's stock, valued at $2,885,801.88. This represents a 8.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $48.14, for a total value of $832,966.42. Following the transaction, the insider now owns 193,601 shares of the company's stock, valued at approximately $9,319,952.14. This represents a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,062,011 shares of company stock valued at $36,892,724 over the last ninety days. Company insiders own 17.71% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席財務官 Oluyemi Okupe 於 1 月 13 日星期一出售了 11,581 股該股票，交易均價為 $24.44，總交易額為 $283,039.64。出售後，首席財務官現在直接持有該公司 118,077 股股票，價值 $2,885,801.88。這代表其持股減少了 8.93%。該交易已在與 SEC 的法律文件中披露，鏈接可通過此處獲取。此外，內部人士 Michael Chi 於 2 月 24 日星期一出售了 17,303 股該股票，交易均價為 $48.14，總價值為 $832,966.42。交易後，內部人士現在持有該公司 193,601 股股票，價值約 $9,319,952.14。這代表其持股減少了 8.20%。該交易的披露信息可在此處找到。內部人士在過去九十天內共出售了 1,062,011 股公司股票，價值 $36,892,724。公司內部人士持有公司股票的 17.71%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds have recently bought and sold shares of the stock. Crewe Advisors LLC purchased a new position in shares of Hims &amp; Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. lifted its stake in Hims &amp; Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its position in shares of Hims &amp; Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Hims &amp; Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims &amp; Hers Health in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金最近買賣了該股票的股份。Crewe Advisors LLC 在第四季度購買了 Hims &amp; Hers Health 的新頭寸，價值約 $28,000。Raleigh Capital Management Inc. 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 $29,000，此前在上個季度購買了額外的 1,100 股。Blume Capital Management Inc. 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 現在擁有該公司 1,200 股股票，價值 $29,000，此前在該期間購買了額外的 600 股。Smartleaf Asset Management LLC 在第四季度將其在 Hims &amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 現在擁有該公司 1,445 股股票，價值 $36,000，此前在上個季度購買了額外的 1,413 股。最後，Summit Securities Group LLC 在第四季度購買了 Hims &amp; Hers Health 的新股份，價值 $38,000。對沖基金和其他機構投資者持有公司 63.52% 的股票。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Hims &amp; Hers Health</li>
<li>每月分紅股票的利弊</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求避難所</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>3 只超賣的傑出七隻股票處於關鍵水平：現在買入？</li>
<li>投資者如何識別併成功交易下跌股票</li>
<li>3M 到中期將達到 $175，且更高的高點很可能出現</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hims & Hers Health (NYSE:HIMS) 股價下跌 8.2% - 你應該賣出嗎？